Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ · Manufacturing · Pharmaceutical preparations
$7.14−$0.3100 (−4.16%) on the dayAs of the close; data may be delayed.
CRBP price, last 12 months
Key stats
- Previous close
- $7.45
- Open
- $7.50
- Day range
- $6.97 – $7.59
- 52-week range
- $6.33 – $20.56
- Volume
- 708.6K
- Avg volume (20 days)
- 1.3M
- Market cap
- $138.1M
Performance
1W−4.6%
1M−36.8%
3M−18.3%
6M−22.7%
YTD−12.3%
1Y−38.0%
vs S&P 500, 1Y−54.8 pts
Technicals and fundamentals
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $138.1M